Compare · CTMX vs HARP
CTMX vs HARP
Side-by-side comparison of CytomX Therapeutics Inc. (CTMX) and Harpoon Therapeutics Inc. (HARP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTMX and HARP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- CTMX is the larger of the two at $796.8M, about 4.8x HARP ($164.7M).
- CTMX has hit the wire 9 times in the past 4 weeks while HARP has been quiet.
- CTMX has more recent analyst coverage (22 ratings vs 6 for HARP).
- Company
- CytomX Therapeutics Inc.
- Harpoon Therapeutics Inc.
- Price
- $3.64-1.49%
- $23.00+0.09%
- Market cap
- $796.8M
- $164.7M
- 1M return
- +22.56%
- -
- 1Y return
- +51.98%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2019
- News (4w)
- 9
- 0
- Recent ratings
- 22
- 6
CytomX Therapeutics Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Harpoon Therapeutics Inc.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Latest CTMX
- A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- SEC Form 4 filed by Director Su Zhen
- SEC Form 8-K filed by CytomX Therapeutics Inc.
- SEC Form 4 filed by Director Young Matthew P.
- SEC Form 4 filed by Director Mohindru Mani
- SEC Form 4 filed by Director Meyers James R
- SEC Form 4 filed by Director Gilbert Halley E
- SEC Form 4 filed by Director Ashworth Alan
- SEC Form 4 filed by Director Jones Elaine V
- Chief Financial Officer Ogden Christopher sold $4,953 worth of shares (1,624 units at $3.05), decreasing direct ownership by 0.55% to 295,324 units (SEC Form 4) to satisfy withholding obligation
Latest HARP
- Seismic Therapeutic Appoints Julie Eastland as Independent Board Director
- Oppenheimer Maintains Outperform on Harpoon Therapeuticsto Outperform
- SEC Form 15-12G filed by Harpoon Therapeutics Inc.
- SEC Form SC 13G filed by Harpoon Therapeutics Inc.
- SEC Form SC 13D/A filed by Harpoon Therapeutics Inc. (Amendment)
- SEC Form EFFECT filed by Harpoon Therapeutics Inc.
- SEC Form EFFECT filed by Harpoon Therapeutics Inc.
- SEC Form EFFECT filed by Harpoon Therapeutics Inc.
- New Leaf Biopharma Opportunities Ii, L.P. returned 1,859,169 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company (SEC Form 4)
- Hunt Ronald was granted 424 shares, returned 1,872,393 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company, closing all direct ownership in the company (SEC Form 4)